Fangping Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fangping Liu has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Rui Li
21 shared publicationsChangwen Li
19 shared publications- Muhammad Ishfaq
Huanggang Normal University
10 shared publications Yicong Chang
10 shared publicationsChenxi Shi
Basic Veterinary Department, College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
9 shared publicationsXinru Jiang
8 shared publications
Latest Publications
- Open Access
Exploratory Assessment of Geographical Variation in Metabolomic Profiles and In Vitro Bioactivities of Wild Schisandra chinensis Berries from the Changbai Mountains, China
Schisandra chinensis (Turcz.) Baill. is widely recognized as a functional berry, yet systematic evaluations of its metabolomic variations and bioactivities across different growing regions remain limited. Berries collected from eight regions in the Changbai Mountains were analyzed using Q-Orbitrap LC-MS-based metabolomics. We identified 18 differential metabolites, with SC1 (Kuandian) exhibiting the highest total lignan content (13.713 mg/g DW). Soils were acidic with variable nutrients; MaxEnt modeling predicted Liaoning as the most suitable habitat. In vitro bioactivities showed considerable variation by origin: SC1 showed the most favorable antioxidant trend; SC7 (Yanbian) demonstrated relatively strong anti-inflammatory and acetylcholinesterase inhibition; SC6 (Baishan) exhibited the most favorable α-amylase inhibition; SC8 (Ning’an) displayed relatively strong α-glucosidase inhibition; and SC3/SC4 (Xiuyan/Xinbin) had the most favorable hepatoprotective effects. Geographic origin is associated with variations in metabolite accumulation and bioactivity, with soil properties and climatic factors showing correlations with these parameters, offering a preliminary basis for quality evaluation and origin prioritization.
Open AccessExploratory Assessment of Geographical Variation in Metabolomic Profiles and In Vitro Bioactivities of Wild Schisandra chinensis Berries from the Changbai Mountains, China
Schisandra chinensis (Turcz.) Baill. is widely recognized as a functional berry, yet systematic evaluations of its metabolomic variations and bioactivities across different growing regions remain limited. Berries collected from eight regions in the Changbai Mountains were analyzed using Q-Orbitrap LC-MS-based metabolomics. We identified 18 differential metabolites, with SC1 (Kuandian) exhibiting the highest total lignan content (13.713 mg/g DW). Soils were acidic with variable nutrients; MaxEnt modeling predicted Liaoning as the most suitable habitat. In vitro bioactivities showed considerable variation by origin: SC1 showed the most favorable antioxidant trend; SC7 (Yanbian) demonstrated relatively strong anti-inflammatory and acetylcholinesterase inhibition; SC6 (Baishan) exhibited the most favorable α-amylase inhibition; SC8 (Ning’an) displayed relatively strong α-glucosidase inhibition; and SC3/SC4 (Xiuyan/Xinbin) had the most favorable hepatoprotective effects. Geographic origin is associated with variations in metabolite accumulation and bioactivity, with soil properties and climatic factors showing correlations with these parameters, offering a preliminary basis for quality evaluation and origin prioritization.
- Open Access
- 27 October 2026
- Published by Elsevier in Poultry Science
- Vol. 105 (12)
Regulating miR-138-5p/SIRT1 axis by Dihydromyricetin alleviates LPS-induced oxidative stress and inflammation in chicken liver damage
- 27 October 2026
- Published by Elsevier in Poultry Science
- Vol. 105 (12)
Open AccessRegulating miR-138-5p/SIRT1 axis by Dihydromyricetin alleviates LPS-induced oxidative stress and inflammation in chicken liver damage
- Open Access
- 8 May 2026
- Published by Elsevier in SSRN Electronic Journal
Protective effect of Dihydromyricetin against Escherichia coli Lipopolysaccharide-induced liver injury in chickens by suppressing TRIF/RIPK3/MLKL Necroptosis signaling pathway
Dihydromyricetin (DHM) is a flavonoid that exerts antioxidant, anti-inflammatory, anti-bacterial properties and so on. Lipopolysaccharide (LPS) is considered the major inducer of liver injury in avian pathogenic Escherichia coli infection can activate the necroptosis by TRIF/RIPK3/MLKL signaling pathway, but the role of DHM on which has not been clearly. The aim of this study was to explore the effect of DHM against LPS-induced liver injury in chickens through TRIF/RIPK3/MLKL necroptosis signaling pathway. The vivo and vitro results showed that LPS treatment significantly increased transaminase activities and hepatic expression levels of TRIF, RIPK3, MLKL. Ultrastructure analysis displayed broken cell membranes, irregular nuclei, and swollen and vacuolated mitochondria in liver, and Annexin V/PI staining presented a large number of hepatocyte deaths. While DHM significantly reduced transaminase activities, repressed hepatic expression of TRIF, RIPK3, MLKL and p-MLKL, improved histological and ultrastructural alterations in the liver, and reduced hepatic expression of IL-6, IL-1β and MOD levels, increased the activities of GSH-Px and SOD. Furthermore, molecular docking results demonstrated that DHM was capable of directly binding to TRIF, RIPK3, and MLKL. Moreover, to explore the underline mechanism of DHM, we used GSK’872, a specific RIPK3 inhibitor, which significantly decreased hepatic RIPK3 and MLKL expression levels, but no significant effect on TRIF expression. In contrast, DHM combined with GSK’872 significantly decrease the expression levels of RIPK3, MLKL, and TRIF, which indicated DHM could inhibit TRIF/RIPK3/MLKL necroptosis signaling in hepatocyte injury. Taken together, DHM could exert repressive effect on TRIF/RIPK3/MLKL necroptosis signaling, ultimately ameliorating LPS-induced liver injury.
- 8 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessProtective effect of Dihydromyricetin against Escherichia coli Lipopolysaccharide-induced liver injury in chickens by suppressing TRIF/RIPK3/MLKL Necroptosis signaling pathway
Dihydromyricetin (DHM) is a flavonoid that exerts antioxidant, anti-inflammatory, anti-bacterial properties and so on. Lipopolysaccharide (LPS) is considered the major inducer of liver injury in avian pathogenic Escherichia coli infection can activate the necroptosis by TRIF/RIPK3/MLKL signaling pathway, but the role of DHM on which has not been clearly. The aim of this study was to explore the effect of DHM against LPS-induced liver injury in chickens through TRIF/RIPK3/MLKL necroptosis signaling pathway. The vivo and vitro results showed that LPS treatment significantly increased transaminase activities and hepatic expression levels of TRIF, RIPK3, MLKL. Ultrastructure analysis displayed broken cell membranes, irregular nuclei, and swollen and vacuolated mitochondria in liver, and Annexin V/PI staining presented a large number of hepatocyte deaths. While DHM significantly reduced transaminase activities, repressed hepatic expression of TRIF, RIPK3, MLKL and p-MLKL, improved histological and ultrastructural alterations in the liver, and reduced hepatic expression of IL-6, IL-1β and MOD levels, increased the activities of GSH-Px and SOD. Furthermore, molecular docking results demonstrated that DHM was capable of directly binding to TRIF, RIPK3, and MLKL. Moreover, to explore the underline mechanism of DHM, we used GSK’872, a specific RIPK3 inhibitor, which significantly decreased hepatic RIPK3 and MLKL expression levels, but no significant effect on TRIF expression. In contrast, DHM combined with GSK’872 significantly decrease the expression levels of RIPK3, MLKL, and TRIF, which indicated DHM could inhibit TRIF/RIPK3/MLKL necroptosis signaling in hepatocyte injury. Taken together, DHM could exert repressive effect on TRIF/RIPK3/MLKL necroptosis signaling, ultimately ameliorating LPS-induced liver injury.
- 27 March 2026
- Published by Elsevier in Research in Veterinary Science
- Vol. 205, 106165
Dihydromyricetin attenuates LPS-induced liver injury in chicks through the JNK signaling pathway
- 27 March 2026
- Published by Elsevier in Research in Veterinary Science
- Vol. 205, 106165
Dihydromyricetin attenuates LPS-induced liver injury in chicks through the JNK signaling pathway
- 14 February 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 362, 121382
Dihydromyricetin ameliorates Salmonella enteritidis-induced pyroptosis and intestinal damage in chickens via modulating NLRP3 inflammasome
- 14 February 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 362, 121382
Dihydromyricetin ameliorates Salmonella enteritidis-induced pyroptosis and intestinal damage in chickens via modulating NLRP3 inflammasome
- 10 October 2025
- Published by Elsevier in Food Control
- Vol. 181
Alpaca nanobody-based sandwich ELISA for specific detection of Salmonella enteritidis in chicken
- 10 October 2025
- Published by Elsevier in Food Control
- Vol. 181
Alpaca nanobody-based sandwich ELISA for specific detection of Salmonella enteritidis in chicken
- Open Access
- 18 March 2025
- Published by Elsevier in Poultry Science
- Vol. 104 (5) , 105034
Dihydromyricetin ameliorates lipopolysaccharide‒induced hepatic injury in chickens by activating the Nrf2/Keap1 pathway and regulating mitochondrial dynamics
- 18 March 2025
- Published by Elsevier in Poultry Science
- Vol. 104 (5) , 105034
Open AccessDihydromyricetin ameliorates lipopolysaccharide‒induced hepatic injury in chickens by activating the Nrf2/Keap1 pathway and regulating mitochondrial dynamics
- 2 December 2024
- Published by Wiley in Journal of Animal Physiology and Animal Nutrition
- Vol. 109 (2) , 610-622
Dihydromyricetin Suppresses Lipopolysaccharide‐Induced Intestinal Injury Through Reducing Reactive Oxygen Species Generation and NOD‐Like Receptor Pyrin Domain Containing 3 Inflammasome Activation
As an integral component of the gram‐negative bacterial cellular envelope, excess production of lipopolysaccharide (LPS) regularly precipitates causing intestinal damage and barrier dysfunction in avian species. Dihydromyricetin (DHM), a naturally occurring constituent in rattan tea, exhibits protective characteristics against various tissue injuries. However, the intervention mechanism of DHM on intestinal injury induced by LPS in chickens has not been determined. Consequently, this study aimed to elucidate the mechanisms through which DHM mitigates LPS‐induced intestinal damage in chickens through the reactive oxygen species (ROS)‐NOD‐like receptor pyrin domain containing 3 (NLRP3) inflammasome. Primary intestinal epithelial cells (IECs) were isolated and cultured from 14‐day‐old specific pathogen free (SPF) chicken embryos, and DHM ranging from 20 to 320 μmol/L increased cell survival rates. Additionally, DHM at 20 and 40 μmol/L demonstrated reduction in oxidative stress and ROS accumulation, mirroring the impact of ROS inhibitor (2.5 mmol/L NAC). DHM efficiently regulated ROS production, thereby augmenting ZO‐1, occludin and claudin‐1 expression to enhance barrier function; upregulating bcl‐2 expression and downregulating bax and caspase‐3 expression to regulate apoptosis and suppressing inflammation in IECs. Suppression of ROS subsequently attenuates NLRP3 inflammasome activation, leading to a remarkable downregulation of IL‐1β, IL‐18 and lactate dehydrogenase (LDH) secretion, consistent with direct inactivation of NLRP3 inflammasome (10 μmol/L MCC950). Notably, DHM diminished IL‐1β and IL‐18 levels and LDH activity via suppression of ROS‐regulated NLRP3 and caspase‐1 expression and activation. In summary, DHM prevents LPS‐induced intestinal impairment by modulating ROS generation and NLRP3 inflammasome activation.
- 2 December 2024
- Published by Wiley in Journal of Animal Physiology and Animal Nutrition
- Vol. 109 (2) , 610-622
Dihydromyricetin Suppresses Lipopolysaccharide‐Induced Intestinal Injury Through Reducing Reactive Oxygen Species Generation and NOD‐Like Receptor Pyrin Domain Containing 3 Inflammasome Activation
As an integral component of the gram‐negative bacterial cellular envelope, excess production of lipopolysaccharide (LPS) regularly precipitates causing intestinal damage and barrier dysfunction in avian species. Dihydromyricetin (DHM), a naturally occurring constituent in rattan tea, exhibits protective characteristics against various tissue injuries. However, the intervention mechanism of DHM on intestinal injury induced by LPS in chickens has not been determined. Consequently, this study aimed to elucidate the mechanisms through which DHM mitigates LPS‐induced intestinal damage in chickens through the reactive oxygen species (ROS)‐NOD‐like receptor pyrin domain containing 3 (NLRP3) inflammasome. Primary intestinal epithelial cells (IECs) were isolated and cultured from 14‐day‐old specific pathogen free (SPF) chicken embryos, and DHM ranging from 20 to 320 μmol/L increased cell survival rates. Additionally, DHM at 20 and 40 μmol/L demonstrated reduction in oxidative stress and ROS accumulation, mirroring the impact of ROS inhibitor (2.5 mmol/L NAC). DHM efficiently regulated ROS production, thereby augmenting ZO‐1, occludin and claudin‐1 expression to enhance barrier function; upregulating bcl‐2 expression and downregulating bax and caspase‐3 expression to regulate apoptosis and suppressing inflammation in IECs. Suppression of ROS subsequently attenuates NLRP3 inflammasome activation, leading to a remarkable downregulation of IL‐1β, IL‐18 and lactate dehydrogenase (LDH) secretion, consistent with direct inactivation of NLRP3 inflammasome (10 μmol/L MCC950). Notably, DHM diminished IL‐1β and IL‐18 levels and LDH activity via suppression of ROS‐regulated NLRP3 and caspase‐1 expression and activation. In summary, DHM prevents LPS‐induced intestinal impairment by modulating ROS generation and NLRP3 inflammasome activation.
- 10 February 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 325, 117887
Ginkgolide C inhibits ROS-mediated activation of NLRP3 inflammasome in chondrocytes to ameliorate osteoarthritis
- 10 February 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 325, 117887
Ginkgolide C inhibits ROS-mediated activation of NLRP3 inflammasome in chondrocytes to ameliorate osteoarthritis
- Open Access
- 24 January 2022
- Published by Springer Nature in Veterinary Research
- Vol. 53 (1) , 1-16
Dihydromyricetin alleviates Escherichia coli lipopolysaccharide-induced hepatic injury in chickens by inhibiting the NLRP3 inflammasome
Dihydromyricetin (DHM), a flavonoid in vine tea, has many pharmacological activities, including anti-inflammatory and antibacterial effects. Lipopolysaccharide is the key inducer of inflammation in avian pathogenic Escherichia coli (E. coli) infection; however, the effect of DHM on E. coli lipopolysaccharide-induced hepatic injury remains unknown. The present study aimed to explore the role of the NLRP3 inflammasome in hepatic injury and the possible protective mechanisms of DHM against hepatic injury in chickens. The results showed that when chickens were administered lipopolysaccharide, liver damage was observed, accompanied by increased levels of serum transaminases and direct bilirubin. Additionally, hepatic expression levels of NLRP3 and caspase-1 p20, the subunit of caspase-1 that is cleaved after NLRP3 activation, significantly increased in liver injury. We found that treatment with MCC950, a specific NLRP3 inhibitor, significantly decreased serum transaminase activities, direct bilirubin content, and hepatic NLRP3 and caspase-1 p20 expression levels. DHM significantly reduced serum transaminase activities and direct bilirubin content and ameliorated histopathological and ultrastructural changes in the liver. DHM decreased hepatic levels of H2O2 and malondialdehyde and increased the activities of superoxide dismutase and glutathione peroxidase. Furthermore, DHM significantly decreased the expression levels of NLRP3, pro-caspase-1 and caspase-1 p20. Moreover, DHM reduced serum lactate dehydrogenase, IL-1β and IL-18 levels and repressed hepatic IL-1β, IL-18 and gasdermin A expression. The results demonstrated that the NLRP3 inflammasome was involved in the mechanism of lipopolysaccharide-induced hepatic injury. Furthermore, DHM could inhibit NLRP3 inflammasome activation and subsequent pyroptosis, eventually ameliorating E. coli lipopolysaccharide-induced liver injury.
- 24 January 2022
- Published by Springer Nature in Veterinary Research
- Vol. 53 (1) , 1-16
Open AccessDihydromyricetin alleviates Escherichia coli lipopolysaccharide-induced hepatic injury in chickens by inhibiting the NLRP3 inflammasome
Dihydromyricetin (DHM), a flavonoid in vine tea, has many pharmacological activities, including anti-inflammatory and antibacterial effects. Lipopolysaccharide is the key inducer of inflammation in avian pathogenic Escherichia coli (E. coli) infection; however, the effect of DHM on E. coli lipopolysaccharide-induced hepatic injury remains unknown. The present study aimed to explore the role of the NLRP3 inflammasome in hepatic injury and the possible protective mechanisms of DHM against hepatic injury in chickens. The results showed that when chickens were administered lipopolysaccharide, liver damage was observed, accompanied by increased levels of serum transaminases and direct bilirubin. Additionally, hepatic expression levels of NLRP3 and caspase-1 p20, the subunit of caspase-1 that is cleaved after NLRP3 activation, significantly increased in liver injury. We found that treatment with MCC950, a specific NLRP3 inhibitor, significantly decreased serum transaminase activities, direct bilirubin content, and hepatic NLRP3 and caspase-1 p20 expression levels. DHM significantly reduced serum transaminase activities and direct bilirubin content and ameliorated histopathological and ultrastructural changes in the liver. DHM decreased hepatic levels of H2O2 and malondialdehyde and increased the activities of superoxide dismutase and glutathione peroxidase. Furthermore, DHM significantly decreased the expression levels of NLRP3, pro-caspase-1 and caspase-1 p20. Moreover, DHM reduced serum lactate dehydrogenase, IL-1β and IL-18 levels and repressed hepatic IL-1β, IL-18 and gasdermin A expression. The results demonstrated that the NLRP3 inflammasome was involved in the mechanism of lipopolysaccharide-induced hepatic injury. Furthermore, DHM could inhibit NLRP3 inflammasome activation and subsequent pyroptosis, eventually ameliorating E. coli lipopolysaccharide-induced liver injury.